Revelation Biosciences (REVB) CEO has 8,521 shares sold for tax withholding

Rhea-AI Filing Summary

Revelation Biosciences, Inc. reported an insider transaction for Chief Executive Officer and director James Rolke. On February 3, 2026, the company sold 8,521 shares of common stock on his behalf at a weighted average price of $1.86 per share.

The sale was made solely to satisfy required tax withholding obligations arising from the vesting of restricted stock awards and was described as mandatory, with no investment discretion exercised by Rolke. After the transaction, he beneficially owned 224,853 shares of common stock, reflecting a 1-for-4 reverse stock split effective January 28, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rolke James

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	8,521	$1.86	$16K

Holdings After Transaction: Common Stock — 224,853 shares (Direct)

Footnotes (1)

1. All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rolke James

(Last) (First) (Middle)

C/O REVELATION BIOSCIENCES, INC.

4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		F		8,521(1)(2)	D	$1.86(3)	224,853(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

2. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ J.P. Galda, as attorney-in-fact for James Rolke	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Revelation Biosciences (REVB) report for James Rolke?

Revelation Biosciences reported a mandatory sale of 8,521 common shares on behalf of CEO and director James Rolke. The issuer sold the shares to cover tax withholding from vested restricted stock awards, rather than a discretionary open-market sale by Rolke himself.

How many Revelation Biosciences (REVB) shares were sold and at what price?

The filing shows 8,521 common shares sold on February 3, 2026, at a weighted average price of $1.86 per share. Footnotes state these shares were sold in multiple transactions between $1.85 and $1.87, inclusive, to satisfy tax withholding obligations.

Why was the Revelation Biosciences (REVB) share sale by the issuer described as mandatory?

The transaction is described as solely to satisfy required tax withholding obligations from the vesting of restricted stock awards. The filing notes the sale was mandatory and that James Rolke did not exercise investment discretion regarding the sale of these shares.

How many Revelation Biosciences (REVB) shares does James Rolke own after the transaction?

After the reported transaction, James Rolke beneficially owned 224,853 shares of Revelation Biosciences common stock. The filing clarifies that all share numbers reflect a 1-for-4 reverse stock split that became effective on January 28, 2026, adjusting the reported holdings.

What stock split affected the share numbers in the Revelation Biosciences (REVB) Form 4?

The Form 4 states that all share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. This means previously outstanding amounts were divided by four, so Rolke’s reported 224,853 post-transaction shares are already adjusted for the reverse split.

Who executed the sale of Revelation Biosciences (REVB) shares reported for James Rolke?

According to the footnotes, the issuer sold the shares on behalf of James Rolke to cover tax withholding from restricted stock vesting. The sale was not initiated as an investment decision by Rolke, and he did not exercise investment discretion over these transactions.